Graham G. Walmsley's Form 4 filing
Olema Pharmaceuticals, Inc. (OLMA) · filed Dec 18, 2023
- Accession no.
- 0000935836-23-000733
- Filed
- Dec 18, 2023
- Trade date
- Sep 12-Dec 5, 2023
- Filing delay
- 97 daysLate
- Rule 10b5-1 plan
- Not checked
This filing lists 4 non-derivative transactions. Open-market purchases total $6.87M. It was filed 97 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Graham G. WalmsleyCIK 0001777517 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 12, 2023 | Common Stock | PPurchaseAcquired | +508,130 | $9.84 | +$4,999,999.2 | 1,668,130 | Indirect | |
| Dec 5, 2023 | Common Stock | PPurchaseAcquired | +31,870 | $14.73 | +$469,445.1 | 1,700,000 | Indirect | |
| Dec 5, 2023 | Common Stock | PPurchaseAcquired | +50,000 | $14.95 | +$747,500 | 1,750,000 | Indirect | |
| Dec 5, 2023 | Common Stock | PPurchaseAcquired | +50,000 | $13.09 | +$654,500 | 1,800,000 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.